Comparative Pharmacology
Head-to-head clinical analysis: GLYCOPYRROLATE versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCOPYRROLATE versus VESICARE LS.
GLYCOPYRROLATE vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glycopyrrolate is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors in the autonomic nervous system, thereby reducing salivary, gastric, and bronchial secretions. It also exhibits antispasmodic effects on gastrointestinal smooth muscle.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
1-2 mg orally 2-3 times daily; maximum 8 mg/day. For parenteral use: 0.1-0.2 mg IV/IM every 4-6 hours as needed.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 0.6-1.2 hours (IM/IV), with prolonged duration in elderly and renal impairment.
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Primarily renal excretion of unchanged drug (85-90%) with biliary/fecal elimination accounting for <10%.
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category C
Category C
Anticholinergic
Anticholinergic